Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular

Related Keywords

San Diego ,California ,United States ,Christina Tartaglia ,Stern Investor Relations Inc ,Nasdaq ,Fate Therapeutics Inc ,Compensation Committee ,Restated Inducement Equity Plan ,Nasdaq Listing Rule ,Fate Therapeutic ,Fate Therapeutics ,Investor Relations ,Region ,